Impact of the Intraoperative Use of Amines in Breast Cancer Surgery on Tumor Recurrence (MASTECTAMINE)

June 1, 2026 updated by: University Hospital, Montpellier

Adrenergic receptors (alpha and beta) are expressed on breast cancer cells, and their stimulation has been shown in experimental studies to promote tumor proliferation and metastasis. Conversely, observational data suggest that beta-blockers may have a protective effect on cancer recurrence. During mastectomy, adrenergic agonists such as catecholamines (e.g., ephedrine, phenylephrine, norepinephrine) and other agents (e.g., clonidine) are frequently used intraoperatively to maintain hemodynamic stability, potentially activating these receptors. While some data suggest that perioperative adrenergic stimulation may influence tumor biology, the clinical impact on cancer recurrence remains unclear.

This retrospective exploratory study aims to evaluate whether the use of adrenergic agents during anesthesia for mastectomy influences tumor recurrence in breast cancer patients. Approximately 250 patients undergoing mastectomy over a 5-year period will be included. The study will assess the association between intraoperative exposure to adrenergic drugs and oncological outcomes, with the goal of better understanding the potential role of perioperative factors in cancer progression.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
    • Hérault
      • Montpellier, Hérault, France, 34000
        • CHU Montpellier

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

all patients operated between 2015 and 2020 for a mastectomy

Description

Inclusion Criteria:

  • patients operated for a mastectomy for breast cancer

Exclusion Criteria:

  • other surgeries for breast cancer not being a mastectomy
  • mastectomy for other conditions than cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
patients operated for a mastectomy for cancer
Patients undergoing mastectomy for cancer management (including both adult and pediatric patients).
Other: collection of health data from electronic medical records
collection of demographic data, key medical history, use of beta-blockers prior to surgery, anesthesia-related data (agents used to maintain anesthesia, regional anesthesia in addition to general anesthesia, intraoperative use of amines), postoperative morphine consumption, survival, and cancer recurrence within 5 years post-surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
cancer recurrence
Time Frame: 5 years post-surgery
either local recurrence or metastases
5 years post-surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Montpellier

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2025

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

May 19, 2026

First Submitted That Met QC Criteria

June 1, 2026

First Posted (Actual)

June 3, 2026

Study Record Updates

Last Update Posted (Actual)

June 3, 2026

Last Update Submitted That Met QC Criteria

June 1, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-11-366

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on collection of health data from electronic medical records

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe